Selective RET Kinase and Its Mutant Inhibitors for the Treatment of Medullary Thyroid Cancer

选择性RET激酶及其突变抑制剂治疗甲状腺髓样癌

• 批准号: 9148246
• 负责人: Hong-Yu Li
• 金额: $ 30.95万
• 依托单位: UNIV OF ARKANSAS FOR MED SCIS
• 依托单位国家: 美国
• 财政年份: 2015
• 资助国家: 美国
• 起止时间: 2015-09-30 至 2020-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/9148246
• 关键词: Active Sites; Animals; Automobile Driving; Benzimidazoles; Binding; Biochemical; Biological Assay; Biological Availability; Biological Markers; Blood Vessels; Cancer cell line; Cause of Death; Cell Proliferation; Cells; Chemicals; Chromosomal Rearrangement; Clinical; Complex; Computer Simulation; Data Analyses; Disease; Dose; Dose-Limiting; Endocrine; Extracellular Domain; Fibroblasts; Gatekeeping; Generations; Genes; Genetic; Goals; Health; Hemorrhage; Human; Hypertension; In Vitro; KDR gene; Lead; Malignant Neoplasms; Marketing; Medical; Modification; Mus; Mutation; Neoplasms; Oncogenes; Oral; Patients; Pharmaceutical Chemistry; Pharmaceutical Preparations; Phospho-Specific Antibodies; Phosphotransferases; Placebos; Point Mutation; Process; Progression-Free Survivals; Proteins; Rattus; Research; Research Proposals; Roentgen Rays; Series; Signal Pathway; Signal Transduction; Site; Specificity; Structure; Structure of thyroid parafollicular cell; Syndrome; Technology; Therapeutic; Therapeutic Agents; Thromboembolism; Thyroid Gland; Time; Toxic effect; Transfection; United States; VEGFR inhibition; Xenograft Model; antiangiogenesis therapy; assay development; base; benzimidazole; cancer cell; cancer survival; cell growth; combat; design; effective therapy; functional group; gain of function; improved; in vitro Assay; in vitro activity; in vivo; inhibitor/antagonist; kinase inhibitor; medullary thyroid carcinoma; mutant; next generation; novel; novel therapeutics; preclinical study; prevent; receptor; screening; tumor growth; tumor progression; tumor xenograft

 DESCRIPTION (provided by applicant): Cancer is the second leading cause of death in United States and new therapeutics are desperately needed to combat the disease. In 1985, the RET (RE-arranged during Transfection) gene was identified as a novel oncogene activated through chromosomal rearrangement. Since then, RET has been identified as a driving oncogene in several cancers, especially for medullary thyroid cancer (MTC). Due to the challenges of identifying a selective RET inhibitor, a treatment for MTC is still an unmet medical need. In an effort to develop a RET kinase inhibitor, a picomolar RET/VEGFR2 clinical candidate has been developed and is currently in preclinical studies. However, the inhibition of VEGFR2 is associated with vascular on-target dose-limiting toxicities, including hypertension in patients for most VEGFR2 inhibitor drugs. We wish to further develop an inhibitor by removing VEGFR2 activity and improving overall selectivity in the kinome, thereby achieving maximal/or complete inhibition of the RET-signaling pathway in patients. We will utilize validated computational models of RET and VEGFR2, fragment-based screening, and potential X-ray crystal structural information to develop a clinical candidate with >30 times RET selectivity over VEGFR2. The resulting selective RET inhibitor could maximally block the RET signaling pathway and will increase MTC survival from months to multiple years.

 描述(申请人提供)：癌症是美国第二大死因，迫切需要新的治疗方法来对抗这种疾病。1985年，RET基因被鉴定为一种新的通过染色体重排激活的癌基因。从那时起，RET已被确定为几种癌症的驱动癌基因，特别是在甲状腺髓样癌(MTC)中。由于寻找选择性RET抑制剂的挑战，MTC的治疗仍然是一个未得到满足的医学需求。为了开发一种RET激酶抑制剂，已经开发了一种微克分子RET/VEGFR2临床候选药物，目前正在进行临床前研究。然而，VEGFR2的抑制与血管靶向剂量限制毒性有关，包括大多数VEGFR2抑制剂药物对患者的高血压。我们希望通过去除VEGFR2的活性和提高动态组的整体选择性来进一步开发一种抑制剂，从而实现对患者RET信号通路的最大/或完全抑制。我们将利用经过验证的RET和VEGFR2的计算模型、基于片段的筛查和潜在的X射线晶体结构信息来开发一种临床候选药物，其RET选择性是VEGFR2的30倍。由此产生的选择性RET抑制剂可以最大限度地阻断RET信号通路，并将使MTC的存活率从几个月增加到数年。